Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia
- Conditions
- SCLC, Extensive Stage
- Interventions
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT06793228
- Locations
- 🇨🇳
The First Affiliated Hospital of Henan University of Science and Technolog, Luoyang, Henan, China
🇨🇳Xinxiang Central Hospital, Xinxiang, Henan, China
🇨🇳Henan cancer hospital,, Zhengzhou, Henan, China
Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- ESCCTotal Neoadjuvant TreatmentPathological Complete Response
- Interventions
- First Posted Date
- 2025-01-08
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06764355
A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Southwest Hospital, China
- Target Recruit Count
- 122
- Registration Number
- NCT06760858
- Locations
- 🇨🇳
The Southwest hospital of AMU, Chongqing, Chongqing, China
BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma
- Conditions
- Hodgkin Lymphoma (Category)
- Interventions
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Xiuhua Sun
- Target Recruit Count
- 100
- Registration Number
- NCT06761911
An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 22
- Registration Number
- NCT06749886
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 460
- Registration Number
- NCT06745908
- Locations
- 🇺🇸
OPN Healthcare INC, Glendale, California, United States
🇺🇸OPN Healthcare INC/ Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus
- Conditions
- HNSCCNeoadjuvant TherapyLysogenic HSV VirusImmunotherapyTargeted Therapy
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT06741982
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06725498
- Locations
- 🇨🇳
Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Target Recruit Count
- 33
- Registration Number
- NCT06722183
- Locations
- 🇩🇪
Klinikum St. Marien Amberg, Amberg, Germany
🇩🇪Charité Campus Virchow Klinikum (CVK), Berlin, Germany
🇩🇪Universitätsklinikum Düsseldorf, Düsseldorf, Germany
Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer
- Conditions
- Advanced and Metastatic NSCLC
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-12-16
- Target Recruit Count
- 430
- Registration Number
- NCT06704620
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.